Notice of Extraordinary General Meeting, proposed company dissolution and delisting

23 Feb 2026 13:17 CET

Oslo, Norway 23 February 2026 - An extraordinary general meeting of PCI Biotech
Holding ASA ('PCI Biotech' or 'Company') will be held at the company's office at
Oslo Cancer Cluster Innovation Park, on 16 March 2026 at 10:00am (CET).

The proposed resolutions include company dissolution and delisting from Euronext
Oslo Børs. The Board of Directors' proposed resolution to dissolve PCI Biotech
is made as there is no longer any operational activity in the Company, nor is it
expected that it will resume such activity or other activities. The wholly owned
subsidiary, PCI Biotech AS, has today resolved to initiate a parallel
dissolution process.

The Board of Directors' proposed resolution to delist the shares from Euronext
Oslo Børs is made based on the non-existent operational activity and limited
asset base. It is in the view of the Board of Directors that the Company is no
longer suitable for listing on a public trading platform and should be delisted
as soon as possible.

The complete notice and proposed resolutions to the extraordinary general
meeting are attached. The notice, including all appendices, will be made
available at PCI Biotech's corporate website www.pcibiotech.com
(http://www.pcibiotech.com).

For further information, please contact:
Ronny Skuggedal, CEO, E-mail: rs@pcibiotech.no
Office: +47 67 11 54 00 Mobile: +47 94 00 57 57

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

More information:
Access the news on Oslo Bors NewsWeb site

666467_PCI Biotech Innkalling EOGF 16 Mars 2026.pdf
666467_PCI Biotech Proposed resolutions EOGM 16 March 2026.pdf
666467_PCI Biotech Notice of EOGM 16 March 2026.pdf
666467_PCI Biotech Forslag til beslutninger EOGF 16 Mars 2026.pdf